| EPA071 | Scaling-up HPV testing for cervical cancer screening in WLHIV in Zambia | E-poster | HIV and co-morbidities |
| EPA072 | Association of HIV viremia with pro-inflammatory fatty acid signatures in pregnancy | E-poster | HIV and co-morbidities |
| EPA073 | MiRNAs as cardiovascular risk biomarkers in people living with HIV (PWH) | E-poster | HIV and co-morbidities |
| EPA074 | Youth HIV-associated neurocognitive disorders: a longitudinal cohort study | E-poster | HIV and co-morbidities |
| EPA075 | What can we learn from the 2021 Aids Healthcare Foundation-Eswatini mortality profile after meeting the UNAIDS 95-95-95 target? | E-poster | HIV and co-morbidities |
| EPLBA06 | Deep down in the gut: analyzing the connection between epithelial cells and ART-induced inflammation | E-poster | HIV and co-morbidities |
| OAA0202 | An immunological signature for subclinical atherosclerosis in people living with HIV-1 receiving antiretroviral therapy | Oral abstract session with live Q&A | HIV and co-morbidities |
| EPA077 | Active tuberculosis co-infection is associated with broad HIV-1 antibody responses | E-poster | HIV and co-infections (TB, viral hepatitis, SARS-CoV2, other) |
| EPA078 | Role of PD-1, TIGIT and TIM3 on NK cell exhaustion and function in HIV/HCV coinfection, and the impact of HCV elimination in the long term | E-poster | HIV and co-infections (TB, viral hepatitis, SARS-CoV2, other) |
| EPA079 | Maternal HIV status and risk of infant M. tuberculosis infection | E-poster | HIV and co-infections (TB, viral hepatitis, SARS-CoV2, other) |